


ACT-Accelerator Facilitation Council


Co-Chairs Report on Emerging Issues

WHO MEMBER STATES BRIEFING

07 JULY 2022

ACT now. ACT together to accelerate the end of the COVID-19 crisis.





Agenda items today

- 1** **Opening remarks**
Bruce Aylward, ACT-A/WHO
- 2** **Council updates, ACT-A achievements & needs**
Professor Olive Shisana, South Africa
- 3** **ACT-A independent evaluation**
Ambassador John-Arne Røttingen, Norway
- 4** **Q&A**


Opening remarks

Bruce Aylward

Global COVID-19 Situation – escalating cases

Cases and Deaths Reported to WHO as of 6 July 2022

- Last week New cases: > 5.1 million
- Last week new deaths: 9327
- Cumulative cases: > 548 million
- Cumulative deaths: > 6.34 million



Change COVID-19 cases & deaths by WHO region

Week 26 (03 Jul to 27 Jun) compared to Week 25 (26 Jun to 20 Jun)

WHO Region	New cases in the last 7 days (%)	Change in new cases in last 7 days *	Cumulative cases (%)	New deaths in last 7 days (%)	Change in new deaths in last 7 days *	Cumulative deaths (%)
Europe	2,629,734 (51.4%)	24.1%	229,151,769 (41.9%)	2,592 (27.79%)	-3.9%	2,028,332 (32.0%)
Americas	1,388,644 (27.1%)	1.2%	163,465,247 (29.9%)	4,607 (49.39%)	10.6%	2,763,502 (43.6%)
Western Pacific	827,117 (16.2%)	3.7%	64,433,670 (11.8%)	1,526 (16.36%)	-11.5%	238,904 (3.8%)
South-East Asia	157,080 (3.1%)	19.9%	58,628,247 (10.7%)	364 (3.90%)	15.9%	790,178 (12.5%)
Eastern Mediterranean	97,561 (1.9%)	30.8%	22,046,436 (4.0%)	112 (1.20%)	34.9%	343,597 (5.4%)
Africa	18,766 (0.4%)	-32.3%	9,134,504 (1.7%)	126 (1.35%)	-46.2%	173,620 (2.7%)
Global	5,118,902 (100%)	13.2%	546,860,637 (100%)	9,327 (100%)	1.2%	6,338,146 (100%)

ACT-Accelerator going forward


Strategic Plan runs to October – a ‘transition plan’ will adjust our ways of working for the period Oct 2022 through Mar 2023

Ensure ongoing implementation:

- continue ACT-A agencies support to countries
- continue work towards equitable access (esp. delivery)
- support countries move to longer term COVID-19 control

Maintain readiness –keep “warm” essential functions to be reactivated for COVID-19 resurgences

Future countermeasures platform to be developed in parallel



 GLOBAL COVID-19
ACCESS TRACKER
www.covid19globaltracker.org



Our ACT-A Facilitation Council Co-Chair leads



Professor Olive Shisana, Co-Chair ACT-A Council

Social Policy Special Adviser to H.E. the President of South Africa




Dr John-Arne Røttingen, Co-Chair ACT-A Council & Chair FinRMWG

Ambassador for Global Health, Ministry of Foreign Affairs, Norway

Council updates, ACT-A achievements and needs


Professor Olive Shisana



ACT-A Facilitation Council

The **Facilitation Council** provides high-level advice, guidance & leadership to facilitate the work of the ACT-Accelerator

ACT-Accelerator | 4 Pillars supported by a Member State-led Council for development of and equitable access to COVID-19 tools



Facilitation Council Working Groups

Set up to **structure and drive** the Facilitation Council's work to provide **high-level political leadership** and enabling advice on global advocacy and resource mobilization.

Tracking & Accelerating Progress

Promoting the global targets for vaccines, therapeutics, diagnostics & PPE.

Co-Chairs:
Indonesia & USA

Financial & Resource Mobilization

Supporting call for higher income countries to contribute a "fair share" of ACT-A funding needs

Chair:
Norway

Vaccine Manufacturing (delivered end-2021)

Enhance vaccine supply to COVAX, from supply chain to developing country production capacities.

Co-Chairs:
South Africa & Germany

Diagnostics & Therapeutics

Assessing current & future barriers to production, demand & access to COVID therapeutics & tests

Co-Chairs:
South Africa & UK

ACT-A Diagnostics & Therapeutics Working Group - update



- **Objective:** assess barriers to production, demand & access to COVID-19 Tx & Dx; recommendations to address barriers
- **Working Group launched:** May 16 - three meetings to date
- **Report:** by Sep 2022; share with Member States, G20, G7, etc

Tracking & Accelerating Progress Working Group – update & plans

I Political outreach to accelerate COVID targets



- *political support to CoVDP priority countries*

II CSO roundtable

- *engagement to accelerate progress*

III Working Group Statement & media briefing

- *actions to speed access & end pandemic*



Finance & RM Working Group - update



Resource mobilization campaign for G7 & G20

Coordinated diplomatic outreach to selected HICs

Consultation on highest priority financing needs

Commitment Tracker covering the two ACT-A budget cycles (2020/21 and 2021/22)

Financing Framework released 9 Feb 2022



ACT-A achievements at July 2022

Vaccines



Total of 3.7B vaccine doses secured through COVAX (**1.56B vaccines delivered**¹)
>US\$ 1.6B to support vaccine delivery in 124 low & middle income-countries.

Tests



US\$ 972m awarded to countries for tests.²
Over **951m tests delivered** by ACT-A¹

Treatment



US\$ 184m awarded to countries for therapeutics & hospital equipment.²
In addition, US\$ 9m worth of COVID-19 **medicines procured** (US\$ 7.9m delivered)

Oxygen



US\$ 560m awarded to countries for medical oxygen²
In addition, US\$ 284m worth of oxygen supplies procured (US\$ 187m delivered)

PPE



US\$ 767m awarded to countries for PPE.²
In addition, S\$ 565m worth of PPE procured (US\$ 463m delivered)

¹As of July 1, 2022, GCAT: www.covid19globaltracker.org

²As of end Q1 2022: [ACT-Accelerator: Quarterly Update Q1: 1 January – 31 March 2022 \(who.int\)](https://www.who.int/publications/m/item/act-accelerator-quarterly-update-q1-1-january-31-march-2022)


Daily COVID-19 testing target: 100/100k pop/day; HICs rate 55x LICs rate

Dramatic testing declines everywhere hinder surveillance & timely detection of Variants



Since April, testing rates have **almost halved** in all income groups

Low testing rates of 4 & 22 per day/100k in LICs & LMICs are in substantial part the result of **funding gaps**

Low testing is an **obstacle to roll out of new oral antivirals**




COVID-19 vaccination needs: primary coverage only 14.8% in LICs




ACT-A current budget: US\$ 5.6B committed, US\$ 11.2B funding gap

Last update: 27 June 2022

ACT-A contributions since October 30, 2021



ACT-A funding gap since October 30, 2021 (US\$ Billion)



Note: all financial commitments can be accessed at <https://www.who.int/publications/m/item/access-to-covid-19-tools-tracker>.

Funding since end-April | tests & treatments severely underfinanced

New funding since end-April 2022



Tests: +US\$ 0.06B, **1.3% of the ask**




Therapeutics: + US\$ 0.05B, **2% of the ask**



Vaccines Delivery: no add'l funding, **still needs US\$ 0.5B**
(*US\$ 0.3B to Unicef and US\$ 0.2B to WHO*)

Most urgently ACT-A financing needs – US\$5.4 billion

- **Vaccines & Tests R&D** to ensure tools evolve ahead of virus
- **PPE, tests & treatments**, incl. novel antivirals, to protect workers, detect new variants, prevent severe disease, save lives
- **In-country delivery** incl. shots into arms¹; roll out new antivirals
- In addition, **contingent financing** for Pandemic Vaccine Pool & Tx



¹ including US\$ 200 million for WHO & US\$ 300 million for UNICEF for vaccine delivery

ACT-A Facilitation Council: status & next steps

The **most recent Facilitation Council** was held on July 6th

Key discussion points:

- escalating status of the COVID-19 pandemic
- waning political momentum in some areas to accelerate uptake of COVID-19 tools
- ACT-A's work on the transition to long-term COVID-19 control

Next Council: plan to hold **Council transition meeting in end-Sept/early-Oct**

A 6-month transition arrangement will be put in place to ensure ongoing accountability & other essential functions as implementation continues into 2023.

ACT-A Independent Evaluation

Ambassador John-Arne Røttingen

ACT-A Independent Evaluation – WHO WGPR statement



The WHO Working Group on strengthening WHO preparedness and response to health emergencies, report to the 75th WHA, May 3, 2022, para 32, p12 [Zero draft report of the Working \(who.int\)](#)

“The WGPR noted the intention of the current co-chairs of ACT-A to initiate an independent evaluation of the platform and its successes and challenges, and noted that this was consistent with calls from many Member States for such an evaluation, and that it may be beneficial to share the results of that evaluation with Member States through the Health Assembly in due course.”

ACT-A Independent Evaluation



Approach

- ACT-A **Facilitation Council** will commission an independent, timely evaluation of ACT-A and its activities, identifying lessons learnt **to inform a future global pandemic preparedness agenda**
- Performed by an **independent evaluation service provider**
- **A multi-pronged approach** includes document review, survey(s) and key informant interviews
- **Qualitative and quantitative**
- **Member States' engagement and input** will be very much appreciated

ACT-A Independent Evaluation Reference Group

- The reference group **co-designs, co-leads** and provides **supervision** to the evaluation
- Countries **chosen** based on expression of interest and level of engagement of Council members; CSOs nominated by the ACT-A CSO platform and PAN
- **6 countries** in addition to Co-Chairs Norway & South Africa: Brazil, Canada, Germany, India, Sweden, Nigeria
- **4 civil society organization** representatives: Pandemic Action Network; 3 representatives of ACT-A CSO Platform (led by WACI Health, STOP AIDS, Global Fund Advocates Network)



ACT-A Independent Evaluation: objectives and deliverables



Objectives

Lessons learnt and way forward:

- mandate
- set-up and structure
- achievement of its objectives & commitments
- resource mobilisation and financing
- gaps and missed opportunities
- way forward



Deliverables

Inception report reviewed by Reference Group

Evaluation report, including context and background; presentation of findings, conclusions and recommendations, reviewed by the Reference Group

Slide deck for dissemination

Timeline & milestones of the ACT-A independent evaluation



How Member States and other stakeholders can get involved in the evaluation



The inputs & perspectives of all stakeholders are highly valued

Please provide contact emails, names & affiliations by July 20:

<https://survey.alchemer.eu/s3/90465196/ACT-A-evaluation-respondents>

Free unsolicited submissions to the evaluation are welcome up to Aug 15 on the theme: *Please tell us what elements of the ACT-A experience you would like to see replicated or NOT replicated in the event of a future pandemic and what preparedness mode capacities need to be sustained* (with name & contact email – see below)


Information on the evaluation, including further guidance on how to submit inputs will be posted on the ACT-A website **next week:**

<https://www.act-a.org/evaluation>



Q&A

- Do you have any questions related to the operations of ACT-A and its priorities?
- What are in your view the key priorities for ACT-A in the global COVID-19 response in the coming months?
- Do you have any questions related to the independent evaluation?
- What should be the main informants & sources of information the evaluators use?



ACTaccelerator

ACCESS TO COVID-19 TOOLS